Skip to Main Content (Press Enter)

Logo UNIBS
  • ×
  • Home
  • Persone
  • Strutture
  • Competenze
  • Pubblicazioni
  • Professioni
  • Corsi
  • Insegnamenti
  • Terza Missione

Competenze & Professionalità
Logo UNIBS

|

Competenze & Professionalità

unibs.it
  • ×
  • Home
  • Persone
  • Strutture
  • Competenze
  • Pubblicazioni
  • Professioni
  • Corsi
  • Insegnamenti
  • Terza Missione
  1. Pubblicazioni

Melanocortin 4 receptor stimulation improves social deficits in mice through oxytocin pathway

Articolo
Data di Pubblicazione:
2018
Abstract:
Several studies on humans and mice support oxytocin's role in improving social behaviour, but its use in pharmacotherapy presents some important limiting factors. To date, it is emerging a pharmacological potential for melanocortin 4 receptor (MC4R) agonism in social deficits treatment. Recently, we demonstrated that the deletion of the NFKB1 gene, which encodes the p50 NF-κB subunit, causes impairment in social behaviours, with reductions in social interactions in mice. In this work, we tested the acute effects of THIQ, a selective melanocortin 4 receptor (MC4R) agonist. THIQ treatment increased social interactions both in wild type and p50−/− mice. In particular, after treatment with THIQ, p50−/− mice showed a prosocial behaviour analogous to that of basal WT mice. Moreover, intranasal treatment with an oxytocin antagonist blocked social interactions induced by THIQ, demonstrating that its prosocial effects are mediated by the oxytocin pathway. The data obtained reinforce using MC4R agonists to ameliorate social impairment in NDDs
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
THIQ; Melanocortin 4 receptor; Oxytocin; p50 KO mouse; Social behaviour
Elenco autori:
Mastinu, Andrea; Premoli, Marika; Maccarinelli, Giuseppina; Grilli, Mariagrazia; Memo, Maurizio; Bonini, Sara Anna
Autori di Ateneo:
BONINI SARA ANNA
MASTINU ANDREA
Neurofarmacologia sperimentale dei disturbi del neurosviluppo
PREMOLI MARIKA
Link alla scheda completa:
https://iris.unibs.it/handle/11379/501401
Pubblicato in:
NEUROPHARMACOLOGY
Journal
  • Assistenza
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Designed by Cineca | 26.5.1.0